Randomization and blinding
BRAIN METASTASIS
This was an open-label study. The participants were randomly assigned 1:1 to the envonalkib and crizotinib groups utilizing a central randomization system and additionally stratified according to brain metastasis status at baseline (yes vs. no) and the number of previous lines of chemotherapy (0 vs. 1).